article thumbnail

Innovation in immuno-oncology: Leading companies in in-vitro T-cell activation

Pharmaceutical Technology

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: In-vitro T-cell activation. Immatics is the leading patent filer in in-vitro T-cell activation.

In-Vitro 130
article thumbnail

New EU in vitro regulations delaying access to treatments

Drug Discovery World

The In Vitro Diagnostic Regulation (IVDR) came into effect in May 2022. The regulation aims to ensure patients’ safety, provide a more transparent framework for IVDs and deliver access to innovative medical technologies. We have to act now to keep clinical trials in Europe and the benefits that they bring to European patients.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Congressional Hearing on LDTs: Split on FDA Regulation but Support for VALID

FDA Law Blog

Gibbs — On March 21, 2024, the House Energy and Commerce held a subcommittee hearing titled “Evaluating Approaches to Diagnostic Test Regulation and the Impact of the FDA’s Proposed Rule.” FDA, which was not invited to participate, would surely have concurred. This seems to have been the outcome that many lawmakers desired.

article thumbnail

Meet the Researcher: Elaine Duncan, University of Glasgow

Drug Discovery World

ED : I’m currently a PhD researcher at the University of Glasgow. My research is focused on developing a 3D in vitro model of adipose tissue which can be used in the lab to help us better understand the complex signalling pathways of metabolic disorders and hopefully allow the discovery of better, curative treatments.

article thumbnail

Scottish drug discovery: advancing new research models

Drug Discovery World

Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. Introduction to the CRUK Beatson Institute The first speaker was Professor Owen Sansom, Director of the Cancer Research UK Beatson Institute, who gave two presentations.

article thumbnail

New anti-evolocumab antibodies could aid drug development

Drug Discovery World

Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. .

article thumbnail

Regulatory, Clinical, and Quality Considerations for Device Research

Advarra

If a new medical device, software as a medical device (SaMD), or in vitro diagnostic (IVD) is poised to successfully make it through the development process to commercialization, sponsors must consider a trifecta of interconnected systems involving: Regulatory strategy and submissions. Meeting with the Regulators. Intended use.